Project description
Proteomics, transcriptomics and bioinformatics for development of novel snakebite therapy
Snakebites can be life-threatening when venom toxins are injected and enter the bloodstream. In areas where immediate access to specialised medical care is limited, bites by venomous snakes cause many thousands of deaths each year. The EU-funded ADDovenom project will use an innovative platform enabling generation of new snakebite treatment, based on a new disruptive protein-based nanoscaffold called ADDomer – a megadalton-sized, thermostable synthetic virus-like particle with 60 high-affinity binding sites to neutralise and eliminate venom toxins from the bloodstream. ADDovenom combines pioneering proteomics, transcriptomics and bioinformatics focusing on snake toxins provoking the most challenging syndromes like haemorrhage and paralysis. The aim is to develop first-in-class neutralising superbinders for snakebite therapy of unprecedented efficacy against the most prevalent Sub-Saharan snakes.
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
BS8 1QU Bristol
United Kingdom
See on map
Participants (5)
4000 Liege
See on map
L35QA Liverpool
See on map
13284 Marseille
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
75794 Paris
See on map
2781-901 Oeiras
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.